We report the case of a 36-year-old woman who was referred to our hospital with a 10-week history of intractable gingivitis. Gingival telangiectases may represent the sign of dermatomyositis. Early identification is essential for diagnosis and immediate treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796783 | PMC |
| http://dx.doi.org/10.1002/jgf2.365 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A missense mutation potentially involved in the pathogenesis of hereditary hemorrhagic telangiectasia: a case report.
J Int Med Res
March 2023
Department of Hematology, Southwest Hospital, First Affiliated Hospital of the Army Medical University, Chongqing 400038, China.
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disease. and gene variants account for up to 96% of all cases, while the remaining cases are caused by or variants, or by currently undiscovered mutations in coding or non-coding regions. Here, we report a 47-year-old man who presented with duodenal bulb bleeding and chronic anemia.
View Article and Find Full Text PDFWe report the case of a 36-year-old woman who was referred to our hospital with a 10-week history of intractable gingivitis. Gingival telangiectases may represent the sign of dermatomyositis. Early identification is essential for diagnosis and immediate treatment.
View Article and Find Full Text PDFGingival telangiectasia of dermatomyositis.
Br J Dermatol
October 2020
Department of Internal Medicine, Division of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Association between oral lesions and disease activity in lupus erythematosus.
J Eur Acad Dermatol Venereol
February 2020
Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Background: Mucosal involvement is frequently seen in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). There is no consensus regarding the prevalence, and a wide range of lesions has been reported. Its prognostic significance is currently unknown and a matter of controversy.
View Article and Find Full Text PDFTelangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report.
Chest
April 2016
Division of Cardiovascular Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN. Electronic address:
Trastuzumab emtansine (T-DM1) is a Food and Drug Administration-approved novel agent for the treatment of HER-2 positive advanced breast cancer. We report a case of pulmonary arterial hypertension (PAH) that we attribute to the use of T-DM1. A 43-year-old woman with stage IV breast cancer presented with dyspnea on exertion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!